Home / Compare / Mounjaro vs Ozempic
Mounjaro vs Ozempic
Mounjaro (tirzepatide) · Ozempic (semaglutide)
The short answer
This comparison is usually asked for the wrong reason. Both are licensed in the UK for type 2 diabetes, and on that question tirzepatide produces greater glucose lowering and greater weight reduction in trials.
But most people searching this are asking about weight loss, and there the answer is different: Mounjaro has a UK weight-management licence and Ozempic does not. If weight is what you are treating, the comparison you want is Mounjaro against Wegovy.
Everything below goes into the detail, with sources on each record.
01Side by side
| Mounjaro (tirzepatide) | Ozempic (semaglutide) | |
|---|---|---|
| UK status | MHRA licensed | MHRA licensed |
| Availability | Prescription only | Prescription only |
| Evidence base | Human RCT, phase 3 | Human RCT, phase 3 |
| Controlled drug | No | No |
| Drug class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
02What is the same
- Both licensed in the UK for type 2 diabetes.
- Both weekly injections, prescription only.
- Both cause weight loss as part of how they work.
- Both act on the GLP-1 receptor, among others.
- Both carry the class cautions, including the January 2026 MHRA pancreatitis alert.
03What actually differs
Receptors, licences and monitoring status.
| Mounjaro | Ozempic | |
|---|---|---|
| Receptors | GLP-1 and GIP | GLP-1 |
| Diabetes licence | Yes | Yes |
| Weight-management licence | Yes | No |
| Additional MHRA monitoring | Yes, black triangle | No |
| UK use since | 2022 | 2018 |
The licence row is the one that answers most searches. Ozempic's UK licence is diabetes only. Semaglutide does have a weight-management licence, but under a different brand, Wegovy, at different doses.
04What the evidence says
For glucose control the relevant head-to-head is SURPASS-2, which compared tirzepatide against semaglutide in type 2 diabetes and favoured tirzepatide on both HbA1c and weight. Funded by Eli Lilly.
For weight specifically, SURMOUNT-5 compared tirzepatide against semaglutide at weight-management doses and again favoured tirzepatide, around 20 per cent against roughly 14 per cent over 72 weeks.
Both trials point the same way. Both were funded by the manufacturer of the winning drug, which is normal and worth knowing.
05Which suits whom
- If you have type 2 diabetes, both are on the table and the choice belongs to whoever manages your diabetes. Existing medicines, kidney function and cardiovascular history all bear on it.
- If you are treating weight, the comparison you want is Mounjaro against Wegovy, not Ozempic.
- If tolerability has been a problem on one, that is a genuine reason to discuss the other.
- If a longer UK track record matters to you, semaglutide has four more years of it.
06Getting either in the UK
Both are available on NHS prescription for type 2 diabetes subject to clinical criteria, and privately against a valid prescription.
For obesity, tirzepatide prescribing entered the GP contract in April 2026 with phased rollout, strict criteria and optional practice participation. Ozempic has no weight-management licence, so there is no equivalent route.
The MHRA issued an alert in February 2026 about falsified Mounjaro pens. Registered UK pharmacy against a valid prescription, or nothing.
07The honest bottom line
For diabetes, tirzepatide performed better in two head-to-head trials, and the choice still belongs to your diabetes team rather than to a comparison table.
For weight, you are comparing the wrong two drugs. Ozempic is not licensed for it in the UK, and the drug you actually want to compare Mounjaro against is Wegovy.
08Common questions
Is Mounjaro better than Ozempic?
In head-to-head trials in type 2 diabetes, tirzepatide produced greater HbA1c reduction and greater weight loss than semaglutide. Better on average across a trial population is not the same as better for an individual, and tolerability matters as much.
Can I get Ozempic for weight loss in the UK?
Not on licence. Its UK licence covers type 2 diabetes. Prescribing it for weight would be off-label, and licensed alternatives exist, including Wegovy and Mounjaro.
Which has fewer side effects?
Both cause gastrointestinal effects and neither has a clear advantage across the board. Individual tolerance varies so much that this is a question only trying it can answer, with a prescriber.
Why is Mounjaro a black triangle medicine?
Because the MHRA has flagged it for additional safety monitoring while the long-term picture is built. It does not mean unsafe. It means reporting suspected side effects through the Yellow Card scheme genuinely matters.
Full record
Tirzepatide
The other licensed drug in this space, and the first approved anywhere to act on two hormone receptors at once.
Full record
Semaglutide
A licensed prescription medicine, and one of the two GLP-1 drugs most people are actually talking about.
Get told when something changes
A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address. Unsubscribe whenever.